AFFILIATES of FCA Venture Partners, based in Nashville's Green Hills village, filed yesterday on an equity raise targeting $175MM.
The filing by FCA Partner and General Counsel Whitney Kalb JD for FCA Health Innovations III QP LP indicated at least $49.8MM raised to date, with 85 investors investing a minimum $100K each. A separate May 15 filing on FCA Health Innovations III AI LP represented $3.1MM invested by 22 investors.
Those filings followed close-on-the-heels of a May 13 announcement that FCA Venture Partners had participated in a $26MM Series A raise for Boulder, Colo.-based BranchLab that was led by McKesson Ventures, which also attracted Sanofi Ventures and AIX Ventures.
BranchLab's website explains, "Biopharma companies and their marketing agencies in-house BranchLab’s platform to model high-value patient and provider populations, activate omnichannel, and measure real-world outcomes without using personal health data."
The BranchLab press release reads, in part: "Pharma commercialization—spanning patient identification, audience segmentation, activation, and real-world measurement—has historically relied on fragmented vendors, delayed analytics, and manual workflows. The result is a system that is data-rich but operationally offline, limiting how quickly teams can learn, adapt, and drive impact... [BranchLab] has built a unified AI platform that puts audience identification, activation, and optimization directly in the hands of pharma teams and their agencies—enabling them to act on high-intent patient and healthcare professional (HCP) audiences in near real time. Today, BranchLab is used by leading pharmaceutical companies and has delivered an average increase of nearly 70% in marketing efficacy across a diverse set of therapeutic areas.
The same press release quotes FCA VP Managing Partner Andrew Bouldin as saying, "Pharma has spent years investing in data and analytics, but much of it still lives outside of production systems. BranchLab’s approach to running models within regulated environments and connecting them directly to execution is a fundamental shift in how commercialization can work. We see this as a meaningful step toward making pharma’s data, and activation systems work together in real time.”
FCA Venture Partners also recently led an "oversubscribed $11 million Series A funding" for New Castle, Dela.-based IgniteData, an entrant in "intelligent clinical trial data automation," according to a press release, Jan. 28.
A year ago, FCA exited Louisville, Ky., based eBlu Solutions in the course of that firm's sale to New Jersey-based CareTria, which supports pharmaceutical care initiation.
In 2022, FCA participated in funding Impiricus, an AI-powered HCP Engagement Engine is used to "ethically connect" healthcare providers to pharma resources, with an eye toward accelerating patient access to treatments.
Also in 2022, filings for FCA Health Innovations II QP LP, a vintage-2020 fund, reached $71MM.
FCA says it manages roughly $330MM AUM and invests in Series Seed to Series B stages. VNC
. updated 0933 19 May 2026